Lv2
156 积分 2025-05-02 加入
A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
3小时前
已关闭
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
3小时前
已完结
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
1个月前
已完结
Trends in Childhood and Adolescent Cancer Incidence Rates in the United States between 2001 and 2022
4个月前
已关闭
IL4/IL13 inhibition via dupilumab reduces malignant T cell proliferation and promotes antitumor immunity in Sezary syndrome
4个月前
已完结
Genome-wide analysis of estrogen receptor binding sites
5个月前
已完结
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
5个月前
已关闭
Estrogen receptor α contributes to T cell–mediated autoimmune inflammation by promoting T cell activation and proliferation
7个月前
已完结
Sex hormones, the anticancer immune response, and therapeutic opportunities
7个月前
已完结
RHOA takes the RHOad less traveled to cancer
7个月前
已完结
皖公网安备34019202002308
